Wegovy® (Semaglutide 2.4mg) an Obesity Treatment for People Living with Obesity in Oman
Muscat, Gulf Tech News :
Novo Nordisk, the Danish leading global healthcare company renowned for its expertise in treating chronic diseases such as diabetes and obesity, announced the availability of Wegovy® in Oman, at a press conference held on Jan 13, 2026.
The event was attended by Novo Nordisk’s General Manager for Gulf Emerging Markets Mr. Venkat Kalyan, The Chief Executive Officer of Muscat Pharmacy & Stores LLC Mr. Jose Sreedharan in the presence of Dr. Noor al Busaidi, President of Oman Diabetes Association & Director of National Diabetes & Endocrine Centre, Dr. Amira Al Kharusi Consultant Bariatric medicine at National Diabetes & Endocrine Centre, as well as Dr. Badr Al Hadrami, President of the Bariatric and Metabolic Surgery Society in Oman, along with distinguished guests and media representatives.
Obesity has emerged as a significant global epidemic, affecting approximately 1 billion individuals worldwide¹. Obesity in the Gulf is rapidly unfolding with the highest rates globally².
Adults in Oman living with obesity represent 36% of the population, and 71% of the population are overweight². With seven out of ten adults in the country affected by weight-related conditions, clinically proven treatment options are expected to play a significant role in easing the burden on healthcare systems and enhancing the quality of life for Omani people.
Statements:
President of Oman Diabetes Association Sayyida Dr Noor Al Busaidi stated:
“In Oman, around 35% of the adult population are affected by obesity and another 66% of the population are either overweight or obese according to the National Health survey in 2017 and we are awaiting updates from the latest survey due to be published soon. We value the work with other stakeholders and partners including pharmaceutical partners in addressing this epidemic through enhancing multidisciplinary approach to care and building the health care professionals’ knowledge and skill capacities, and with the introduction of advanced and proven treatments, We are optimistic that the launch of Wegovy® in Sultanate of Oman is an important step with great clinical management potentials. We will continue to work together to achieve our common goal and that is to limit the burden of obesity while working also on the prevention side, educating people and raising awareness and participating in obesity intervention programs.”
Dr. Amira Al Kharusi Consultant Bariatric medicine at National Diabetes & Endocrine Centre shared that:
“Obesity represents one of the most significant threats to population health and healthcare sustainability in Oman. Addressing it requires leadership, long‑term vision, and coordinated policy action across sectors. By prioritizing prevention, strengthening clinical care, and investing in evidence‑based strategies, the Ministry of Health can lead a transformative response-one that protects the health of current and future generations.
In this context, the introduction of modern anti‑obesity medications such as Wegovy®️ (semaglutide 2.4 mg) adds an important dimension to the national treatment pathway. When used appropriately and under medical supervision, Wegovy®️ can support patients who need clinically proven options beyond lifestyle modification alone. Integrating such therapies into Oman’s broader obesity‑management framework enhances treatment effectiveness, supports earlier intervention, and helps reduce long‑term complications.”
President of the Oman Bariatric and Metabolic Surgery Society Dr. Badr Al Hadrami emphasized:
“Obesity is a serious and chronic disease, and a leading contributor to multiple comorbidities such as type 2 diabetes and cardiovascular conditions. He noted that “Oman ranks among the highest globally in obesity prevalence, which underscores the urgent need for collaborative efforts across all sectors to address this growing public health challenge”. Also highlighted the importance of GLP-1 therapies like Wegovy®️, which play a vital role in improving health outcomes and saving lives by offering patients an effective tool to manage obesity
